Merdury Biopharmaceutical (6932.TWO) Stock Price

Merdury Biopharmaceutical Price

CLOSED
7.04
​
Market closed

Revenue has compounded at 36.1% per year over the past 2 years to 4.96 M TWD. Merdury Biopharmaceutical's net margin stands at -1,018.9%, up from -1,166.0% several years earlier.

Merdury Biopharmaceutical stock price

Access this data via the Eulerpool API

Merdury Biopharmaceutical business model & stock analysis

Mercury Biopharmaceutical Corp. manufactures pharmaceutical products. The company is headquartered in Taipei, New Taipei and currently employs 13 full-time employees. The company went IPO on 2022-12-23. The firm mainly focuses on the development of drugs that do not meet special medical needs, difficult generic drugs and second-class new drugs. With the self-developed and multi-national patented drug development platform StackDose, the Company can develop products that can achieve controllable time-dissolving (instant or sustained release) tablets, thereby controlling the time for the drug to take effect. The main products include Sildenafil, Metformin, Tadalafil, Zolpidem, angina drugs, migraine drugs, multi-ingredient antihypertensive drugs and others. The products are mainly sold in Taiwan and the United States.

Frequently asked questions about Merdury Biopharmaceutical

Converted at the current exchange rate, the Merdury Biopharmaceutical share trades at 0.20 EUR (7.04 TWD).

The revenue cannot currently be calculated for Merdury Biopharmaceutical.

The profit cannot currently be calculated for Merdury Biopharmaceutical.

The P/E ratio cannot be calculated for Merdury Biopharmaceutical at the moment.

The P/S cannot be calculated for Merdury Biopharmaceutical currently.

The Eulerpool Quality Score for Merdury Biopharmaceutical is 2/10.

The ISIN of Merdury Biopharmaceutical is TW0006932007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Merdury Biopharmaceutical is 6932.TWO. The ticker symbol is used to trade Merdury Biopharmaceutical shares on the stock exchange.

Fair ValueTerminal
5.84 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website merdury.com
Country
Taiwan
Currency
TWD
Initial public offering
Dec 23, 2022
ISIN
TW0006932007
Cusip
Y5S4MT106
Market capitalization
2.99 B TWDMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
13.62
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-26.08 %
Last updated Oct 9, 2026, 5:11 PM

Merdury Biopharmaceutical Peer Group

Merdury Biopharmaceutical FIGI

6932:TT (Taipei Stock Exchange) · BBG01BYYBXR8